- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05917951
Study on Determine the Utilisation and Clinical Outcomes of Evusheld in COVID-19 PrEP in China (CLEAR)
Study on Clinical Use of Evusheld (AZD7442) in the Real-world Setting - A Multi-Centre, Single-arm, Observational Study to Determine the Utilisation and Clinical Outcomes of Evusheld in China
Study Overview
Status
Conditions
Detailed Description
COVID-19 has a spectrum of clinical manifestations and multisystem organ involvement due to SARS-CoV-2, viral dynamics may correlate to the severity of illness and disease outcomes. Despite the increase in COVID-19 vaccine roll-out, many individuals still remain at high risk of breakthrough infection and many of these individuals are also at higher risk of poor COVID-19 outcomes. In the US about 3% of the adult population is moderately to severely immunocompromised, leading to increased vulnerability to COVID-19.
AZD7442 is a combination of 2 human long acting antibodies, which was selected for maximal potency and demonstrated synergistic neutralization of SARS-CoV-2 in vitro. AZD7442 are 2 monoclonal antibodies that independently neutralize SARS-CoV-2 with high potency in vitro. AZD7442 targets SARS-CoV-2 spike protein to prevent virus entry into host cells.
PROVENT is a Phase III study in participants at an increased risk for inadequate response to COVID-19 vaccine, an increased risk of exposure to SARS-CoV-2 or both. The study met the primary endpoint of reduction in the incidence of symptomatic COVID-19 with TIXA/CILGA compared with placebo, risk reduction 76.7% (95% CI, 46.0-90.0), and longer (median 6-month) follow-up showed a risk reduction of 82.8%, in 5172 patients who did not have a SARS-CoV-2 RT-PCR-positive COVID-19 infection at baseline. Most adverse events were mild or moderate in intensity, with the overall adverse event profile over a median follow-up of 6 months remaining similar to the primary safety analysis. At either the primary or 6-month analyses, there were no cases of severe/critical COVID-19 in those treated with AZD7442. In the placebo arm, there were 5 cases of severe/critical COVID-19 in total.
Although the PROVENT trial was invaluable in demonstrating AZD7442's ability to prevent symptomatic infection, it was conducted in highly controlled environments using a rigorous protocol, which does not accurately reflect the patient experience in clinical practice. Furthermore, the sample size of Asian population in phase 3 clinical trials is small (110 subjects in AZD7442 group and 60 subjects in placebo group), and there is very limited clinical trial/real-world data in Chinese population is reported.
Studies are therefore needed to understand who is being administered AZD7442 in the real world, the frequency of COVID-19 related events, and healthcare resource utilisation (HCRU). Also, important to understand is the potential impact that AZD7442 administration may have on COVID-19 risk behaviours (particularly shielding and other preventive measures), which may in turn influence interpretation of AZD7442 effectiveness results. Such information is imperative to inform clinical decision-making for the care of this relatively vulnerable population.
Therefore, this current study aims to describe the utilisation and clinical outcomes of AZD7442 in Chinese population for pre-exposure prophylaxis. Although this study will not evaluate the effectiveness of AZD7442, the descriptive results may guide further development of studies to assess real world effectiveness of AZD7442. The study is planned to be conducted in approximately 100 sites in China.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Hainan
-
Qionghai, Hainan, China
- (2) Ruijin-Hainan Hospital Shanghai Jiaotong University School of Medicine (Hainan Boao Research Hospital)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria
Subjects who fulfil all the following inclusion criteria will be eligible to participate in the study:
- Individuals receiving AZD7442 before enrolment date or have been prescribed or have planned to administrate at enrolment date.
- Individuals willing and able to sign informed consent signed.
Exclusion Criteria
Subjects who fulfil any of the following exclusion criteria will not be eligible to participate in the study:
• Individuals currently participating in interventional clinical trials of SARS-CoV-2 prophylactic or treatments.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To describe the baseline demographic and clinical characteristics of individuals receiving AZD7442 for pre-exposure prophylaxis
Time Frame: up to 12 months before first administration of AZD7442 for pre-exposure prophylaxis
|
|
up to 12 months before first administration of AZD7442 for pre-exposure prophylaxis
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To describe the baseline demographic and clinical characteristics of individuals receiving AZD7442 for pre-exposure prophylaxis by population subgroup of key basic disease.
Time Frame: up to 12 months before first administration of AZD7442 for pre-exposure prophylaxis
|
To describe the baseline demographic and clinical characteristics of individuals receiving AZD7442 for pre-exposure prophylaxis by population subgroup of immune compromised disease, including haematological malignancies, solid organ transplant, autoimmune disease, solid tumour, chronic kidney disease (CKD; including dialysis) and others
|
up to 12 months before first administration of AZD7442 for pre-exposure prophylaxis
|
To describe the incidence of SARS-CoV-2 infection (asymptomatic or symptomatic), medically-attended COVID-19, and COVID-19 related hospitalization and death up to 6 months after first administrationxposure prophylaxis of AZD7442 for pre-e
Time Frame: 6 months after first administration of AZD7442 for pre-exposure prophylaxis
|
|
6 months after first administration of AZD7442 for pre-exposure prophylaxis
|
To describe the incidence of all-cause hospitalization and mortality during the 6 months after first administration of AZD7442 for pre-exposure prophylaxis
Time Frame: during the 6 months after first administration of AZD7442 for pre-exposure prophylaxis
|
|
during the 6 months after first administration of AZD7442 for pre-exposure prophylaxis
|
To describe COVID-19 risk behaviours at the time of AZD7442 injection and during the 6 months after first administration of AZD7442 for pre-exposure prophylaxis
Time Frame: during the 6 months after first administration of AZD7442 for pre-exposure prophylaxis
|
• AstraZeneca-developed Risk Behaviour Questionnaire (Appendix A)
|
during the 6 months after first administration of AZD7442 for pre-exposure prophylaxis
|
To describe COVID-19-related healthcare resource utilisation (HCRU) during the 6 months after first administration of AZD7442 for pre-exposure prophylaxis
Time Frame: during the 6 months after first administration of AZD7442 for pre-exposure prophylaxis
|
|
during the 6 months after first administration of AZD7442 for pre-exposure prophylaxis
|
To describe the safety of AZD7442 during the 6 months after first administration of AZD7442
Time Frame: during the 6 months after first administration of AZD7442 for pre-exposure prophylaxis
|
|
during the 6 months after first administration of AZD7442 for pre-exposure prophylaxis
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To describe the incidence of long COVID syndrome following AZD7442 first administration for pre-exposure prophylaxis
Time Frame: 12 weeks from first onset of COVID-19 symptoms
|
|
12 weeks from first onset of COVID-19 symptoms
|
To describe the baseline and repeat administration(s) of AZD7442
Time Frame: when receive AZD7442
|
Number, frequency of subjects administered AZD7442 by:
|
when receive AZD7442
|
To describe the usage purpose of AZD7442
Time Frame: when receive AZD7442
|
Number, proportion of subjects administered AZD7442 by:
|
when receive AZD7442
|
To describe the demographic and clinical characteristics of SARS-CoV-2 infection, medically attended COVID-19, and COVID-19 related hospitalized cases occurring in comparison to non-cases.
Time Frame: 6 months following AZD7442 first administration for pre-exposure prophylaxis
|
|
6 months following AZD7442 first administration for pre-exposure prophylaxis
|
To describe SARS-CoV-2 RNA viral load levelsafter symptomatic SARS-CoV-2 infection within 29 days after first administration of AZD7442 for treatment
Time Frame: within 29 days after first administration of AZD7442 for treatment
|
• SARS-CoV-2 RNA viral load levels and changes in nasal swabs during hospitalization up to 29 days
|
within 29 days after first administration of AZD7442 for treatment
|
To describe the neutralising responses against SARS-CoV-2 subvariants of AZD7442 in serum (if applicable)
Time Frame: 6 months following AZD7442 first administration for pre-exposure prophylaxis
|
• Post treatment GMTs and GMFRs from baseline value through 6 month after single IM dose in SARS-COV-2 neutralizing antibodies (pseudo neutralization assay)
|
6 months following AZD7442 first administration for pre-exposure prophylaxis
|
To describe severe COVID-19 related hospitalization and ICU after symptomatic SARS-CoV-2 infection within 29 days after first administration of AZD7442 for treatment
Time Frame: within 29 days after first administration of AZD7442 for treatment
|
|
within 29 days after first administration of AZD7442 for treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jieming Qu, Doctor, 18917762988
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D8850R00019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin... and other collaboratorsRecruitingCOVID-19 | Post-COVID-19 Syndrome | Post-Acute COVID-19 | Acute COVID-19China
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany